Physician profile
Robert L Johnson
NPI 1528019486
$2,659.02
in general payments reported to CMS, 2019-2025
14 companies · $338 in 2025
The $338 reported for 2025 was more than what a typical Optometrist provider received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $327 · 2020: $192 · 2021: $175 · 2022: $542 · 2023: $490 · 2024: $595 · 2025: $338.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,418 · Education: $4.78.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,418.38 |
| Education | $4.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb Americas INC. | $1,418.72 | 2022-2025 | Infuse, Miebo, Xiidra |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $381.22 | 2019-2021 | |
| Alcon Vision LLC | $185.69 | 2023-2025 | Hydrus Microstent |
| Johnson & Johnson Vision Care, INC. | $137.77 | 2019-2022 | |
| Coopervision INC. | $134.26 | 2019-2024 | Myday Contact Lens |
| Sun Pharmaceutical Industries INC. | $107.56 | 2023-2025 | Cequa |
| Abbvie INC. | $60.94 | 2023-2024 | |
| Notal Vision, INC. | $44.68 | 2022 | |
| Oyster Point Pharma, INC. | $44.05 | 2022-2023 | Tyrvaya |
| Allergan, INC. | $40.29 | 2020-2021 | |
| Thea Pharma INC. | $40.00 | 2023 | |
| Mallinckrodt Hospital Products INC. | $30.12 | 2022 | |
| Novartis Pharmaceuticals Corporation | $21.44 | 2020 | |
| Optos, INC. | $12.28 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Johnson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.